Immunovant Inc: Strong Autoimmune Drug Pipeline Drives Nasdaq Gains & $6.31B Market CapDiscover how Immunovant Inc is reshaping autoimmune care with a $6.31 billion biotech strategy, stock rebound, and cutting‑edge drug pipeline.IMMUNOVANT INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 09/11/2026, 13:22 2 minutes to read
Immunovant Inc: Leading Autoimmune Drug Innovation & Strong Nasdaq Growth in 2026Immunovant Inc is a New York‑based biopharma innovating autoimmune therapies, trading on Nasdaq with a $6.3 B market cap and a focus on breakthrough treatments.IMMUNOVANT INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 08/11/2026, 16:03 3 minutes to read